114 related articles for article (PubMed ID: 27469917)
21. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
[TBL] [Abstract][Full Text] [Related]
22. Multiple solid pancreatic lesions: Prevalence and features of non-malignancies on dynamic enhanced CT.
Zhu L; Dai MH; Wang ST; Jin ZY; Wang Q; Denecke T; Hamm B; Xue HD
Eur J Radiol; 2018 Aug; 105():8-14. PubMed ID: 30017302
[TBL] [Abstract][Full Text] [Related]
23. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
24. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?
Amthauer H; Ruf J; Böhmig M; Lopez-Hänninen E; Rohlfing T; Wernecke KD; Plöckinger U; Gutberlet M; Lemke AJ; Steinmüller T; Wiedenmann B; Felix R
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):342-8. PubMed ID: 14652697
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of 99mTc-MDP SPECT/spiral CT combined with three-phase bone scintigraphy in assessing suspected bone tumors in patients with no malignant history.
Zhang Y; Shi H; Li B; Xiu Y; Cai L; Gu Y; Chen S
Nucl Med Commun; 2015 Jul; 36(7):686-94. PubMed ID: 25757199
[TBL] [Abstract][Full Text] [Related]
29. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
30. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.
Belousova E; Karmazanovsky G; Kriger A; Kalinin D; Mannelli L; Glotov A; Karelskaya N; Paklina O; Kaldarov A
Clin Radiol; 2017 Feb; 72(2):150-158. PubMed ID: 27890421
[TBL] [Abstract][Full Text] [Related]
31. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
Partelli S; Rinzivillo M; Maurizi A; Panzuto F; Salgarello M; Polenta V; Delle Fave G; Falconi M
Neuroendocrinology; 2014; 100(4):293-9. PubMed ID: 25301162
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
[TBL] [Abstract][Full Text] [Related]
33. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization.
Jensen RT; Gibril F; Termanini B
Yale J Biol Med; 1997; 70(5-6):481-500. PubMed ID: 9825476
[TBL] [Abstract][Full Text] [Related]
34. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
35. CT in the differentiation of pancreatic neoplasms--progress report.
Gritzmann N; Macheiner P; Hollerweger A; Hübner E
Dig Dis; 2004; 22(1):6-17. PubMed ID: 15292690
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
[TBL] [Abstract][Full Text] [Related]
37. Magnetic Resonance Imaging May Be Able to Identify the Origin of Neuroendocrine Tumor Liver Metastases.
Barat M; Soyer P; Al Sharhan F; Terris B; Oudjit A; Gaujoux S; Coriat R; Hoeffel C; Dohan A
Neuroendocrinology; 2021; 111(11):1099-1110. PubMed ID: 33190136
[TBL] [Abstract][Full Text] [Related]
38. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
39. Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?
Toshima F; Inoue D; Komori T; Yoshida K; Yoneda N; Minami T; Matsui O; Ikeda H; Gabata T
Jpn J Radiol; 2017 May; 35(5):242-253. PubMed ID: 28258323
[TBL] [Abstract][Full Text] [Related]
40. Spiral multi-phase CT in evaluating resectability of pancreatic carcinoma.
Huang QJ; Xu Q; Wang XN; Zhang LL
Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):614-9. PubMed ID: 14607698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
